Back to search results

NeuroGuard: Psilocybin for Preventing Chemo-induced Neuropathy

This study, called NeuroGuard, is looking into whether psilocybin can help prevent or lessen nerve damage (neuropathy) caused by chemotherapy. You might be able to join if you have breast, colorectal, or head and neck cancer and are scheduled to receive certain types of chemotherapy (platinum-based or taxanes). Researchers are comparing a 25 mg dose of psilocybin to a 1 mg dose of psilocybin and to standard care (no study drug). The main goal is to see if psilocybin can reduce the worsening of neuropathy symptoms. The study aims to enroll 83 participants, but its current status is unclear.

Study design
This interventional study plans to enroll 83 participants. It compares different doses of psilocybin to standard care.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Safety and side effects will be measured through study completion, which is an average of 1 year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07227909

NeuroGuard: Psilocybin Trial for Preventing Chemo-induced Neuropathy

Not Yet Recruiting
PHASE2Ages 18+InterventionalSupportive care
M.D. Anderson Cancer Center
~83 participants
Updated 2026-08-12 on ClinicalTrials.gov
What's tested:Psilocybin (drug)Standard of Care (SOC)

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Safety and adverse events (AEs)
Measured over Through study completion; an average of 1 year

Conditions

Psilocybin
Neuropathy

Explore related trials

Breast CarcinomaColorectal CarcinomaMalignant Head and Neck Neoplasm

Where it's being run

1 sites across 1 states
Texas1

Study leadership

  • Moran Amit, MD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center

Who to contact

Moran Amit, MD
[email protected]
713-794-5304
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Exclusion

Postmenopausal (no menses in greater than or equal to 12 consecutive months).
History of hysterectomy or bilateral salpingo-oophorectomy.
Ovarian failure (Follicle Stimulating Hormone and Estradiol in menopausal range, who have received Whole Pelvic Radiation Therapy).
History of bilateral tubal ligation or another surgical sterilization procedure.

What this trial measures

  • Safety and adverse events (AEs)Through study completion; an average of 1 year

    Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0